[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 2 sources · 29 days · First seen · Last updated

Vertex Pharmaceuticals acquisition of Crinetics

Overview

In early July 2026, Vertex Pharmaceuticals announced a $10 billion deal to acquire Crinetics, signaling a major expansion of its drug pipeline. By early August, Vertex reported a stronger-than-expected second‑quarter performance, driven by robust sales of its cystic fibrosis therapies Alyftrek and Trikafta. The company raised the upper end of its annual revenue forecast to $13.1‑$13.2 billion, explicitly noting that the outlook excludes the pending Crinetics acquisition, which is expected to close in the third quarter.

The sequence shows Vertex moving from the strategic announcement of a large acquisition to leveraging its existing CF drug portfolio to boost earnings, while awaiting the completion of the Crinetics deal.

Entities

Crinetics · Vertex Pharmaceuticals · cystic fibrosis · Trikafta · Alyftrek

Timeline

  1. 22 days ago

    [BUSINESS] 2 sources
    Vertex Pharmaceuticals lifts revenue outlook on strong cystic fibrosis drug sales

    Vertex raised its annual revenue target to $13.1‑$13.2 bn, driven by strong cystic fibrosis drug sales, while pending a $10 bn Crinetics acquisition.

  2. about 2 months ago

    [BUSINESS] 10 sources
    Vertex Pharmaceuticals to acquire Crinetics for $10 billion

    Vertex Pharma agreed to buy Crinetics for about $10 billion ($85 per share), adding endocrine drugs PALSONIFY and atumelnant, with the deal slated to close in Q3 2026; Crinetics stock jumped ~100% as Vertex’s t

Sources

paparazzi.com.ar · wtvbam.com